Literature DB >> 23422914

Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa.

Christian van Delden1, Malcolm G P Page, Thilo Köhler.   

Abstract

BAL30072 is a monosulfactam conjugated with an iron-chelating dihydroxypyridone moiety. It is active against Gram-negative bacteria, including multidrug-resistant Pseudomonas aeruginosa. We selected mutants with decreased susceptibilities to BAL30072 in P. aeruginosa PAO1 under a variety of conditions. Under iron-deficient conditions, mutants with overexpression of AmpC β-lactamase predominated. These mutants were cross-resistant to aztreonam and ceftazidime. Similar mutants were obtained after selection at >16× the MIC in iron-sufficient conditions. At 4× to 8× the MIC, mutants with elevated MIC for BAL30072 but unchanged MICs for aztreonam or ciprofloxacin were selected. The expression of ampC and the major efflux pump genes were also unchanged. These BAL30072-specific mutants were characterized by transcriptome analysis, which revealed upregulation of the Fe-dicitrate operon, FecIRA. Whole-genome sequencing showed that this resulted from a single nucleotide change in the Fur-box of the fecI promoter. Overexpression of either the FecI ECF sigma factor or the FecA receptor increased BAL30072 MICs 8- to 16-fold. A fecI mutant and a fecA mutant of PAO1 were hypersusceptible to BAL30072 (MICs < 0.06 μg/ml). The most downregulated gene belonged to the pyochelin synthesis operon, although mutants in pyochelin receptor or synthesis genes had unchanged MICs. The piuC gene, coding for a Fe(II)-dependent dioxygenase located next to the piuA iron receptor gene, was also downregulated. The MICs of BAL30072 for piuC and piuA transposon mutants were increased 8- and 16-fold, respectively. We conclude that the upregulation of the Fe-dicitrate system impacts the expression of other TonB-dependent iron transporters and that PiuA and PiuC contribute to the susceptibility of P. aeruginosa PAO1 to BAL30072.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422914      PMCID: PMC3632904          DOI: 10.1128/AAC.02474-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  In vitro antibacterial activity of KP-736, a new cephem antibiotic.

Authors:  T Maejima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups.

Authors:  H Nikaido; E Y Rosenberg
Journal:  J Bacteriol       Date:  1990-03       Impact factor: 3.490

Review 3.  The pyocins of Pseudomonas aeruginosa.

Authors:  Yvon Michel-Briand; Christine Baysse
Journal:  Biochimie       Date:  2002 May-Jun       Impact factor: 4.079

4.  PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa.

Authors:  Jesús Blázquez; José-María Gómez-Gómez; Antonio Oliver; Carlos Juan; Vivek Kapur; Soledad Martín
Journal:  Mol Microbiol       Date:  2006-08-31       Impact factor: 3.501

5.  Exogenous induction of the iron dicitrate transport system of Escherichia coli K-12.

Authors:  L Zimmermann; K Hantke; V Braun
Journal:  J Bacteriol       Date:  1984-07       Impact factor: 3.490

6.  Ferric citrate transport in Escherichia coli requires outer membrane receptor protein fecA.

Authors:  W Wagegg; V Braun
Journal:  J Bacteriol       Date:  1981-01       Impact factor: 3.490

7.  In vitro and in vivo evaluation of Ro 09-1428, a new parenteral cephalosporin with high antipseudomonal activity.

Authors:  M Arisawa; Y Sekine; S Shimizu; H Takano; P Angehrn; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

8.  Cloning, characterization, and expression in Escherichia coli of the Streptomyces clavuligerus gene encoding deacetoxycephalosporin C synthetase.

Authors:  S Kovacevic; B J Weigel; M B Tobin; T D Ingolia; J R Miller
Journal:  J Bacteriol       Date:  1989-02       Impact factor: 3.490

9.  Intracellular activation of albomycin in Escherichia coli and Salmonella typhimurium.

Authors:  V Braun; K Günthner; K Hantke; L Zimmermann
Journal:  J Bacteriol       Date:  1983-10       Impact factor: 3.490

10.  Regulation of toxA and regA by the Escherichia coli fur gene and identification of a Fur homologue in Pseudomonas aeruginosa PA103 and PA01.

Authors:  R W Prince; D G Storey; A I Vasil; M L Vasil
Journal:  Mol Microbiol       Date:  1991-11       Impact factor: 3.979

View more
  19 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Promysalin Elicits Species-Selective Inhibition of Pseudomonas aeruginosa by Targeting Succinate Dehydrogenase.

Authors:  Colleen E Keohane; Andrew D Steele; Christian Fetzer; Jittasak Khowsathit; Daria Van Tyne; Lucile Moynié; Michael S Gilmore; John Karanicolas; Stephan A Sieber; William M Wuest
Journal:  J Am Chem Soc       Date:  2018-01-24       Impact factor: 15.419

Review 3.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

4.  Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy.

Authors:  Aryun Kim; Amy Kutschke; David E Ehmann; Sara A Patey; Jared L Crandon; Elise Gorseth; Alita A Miller; Robert E McLaughlin; Christina M Blinn; April Chen; Asha S Nayar; Brian Dangel; Andy S Tsai; Michael T Rooney; Kerry E Murphy-Benenato; Ann E Eakin; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

5.  Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Lucile Moynié; Alexandre Luscher; Dora Rolo; Daniel Pletzer; Antoni Tortajada; Helge Weingart; Yvonne Braun; Malcolm G P Page; James H Naismith; Thilo Köhler
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.

Authors:  Saquib Malik; Monica Kaminski; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects.

Authors:  Marion Straubinger; Holger Blenk; Kurt G Naber; Florian M E Wagenlehner
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 8.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 9.  Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics.

Authors:  Phillip E Klebba; Salete M C Newton; David A Six; Ashish Kumar; Taihao Yang; Brittany L Nairn; Colton Munger; Somnath Chakravorty
Journal:  Chem Rev       Date:  2021-03-16       Impact factor: 60.622

10.  Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance.

Authors:  Patricia J Simner; Stephan Beisken; Yehudit Bergman; Andreas E Posch; Sara E Cosgrove; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.